Crossmark

545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.545

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Grignani, Giovanni

Rutkowski, Piotr

Lebbe, Celeste

Prinzi, Natalie

Grob, Jean-jaques

Tanda, Enrica Teresa

Guida, Michele

Burgess, Melissa

Pulini, Jennifer

Shankar, Sadhna

Tian, Chuan

Bhatia, Shailender
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03599713 at ClinicalTrials.gov

Documents that mention this clinical trial

Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)
https://doi.org/10.1136/jitc-2025-012478

545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)
https://doi.org/10.1136/jitc-2021-sitc2021.545